- Home
- INZY vs TWIN Comparison
INZY vs TWIN Comparison
Compare INZY & TWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- TWIN
- Stock Information
- Founded
- INZY 2015
- TWIN 1918
- Country
- INZY United States
- TWIN United States
- Employees
- INZY N/A
- TWIN N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- TWIN Industrial Machinery/Components
- Sector
- INZY Health Care
- TWIN Industrials
- Exchange
- INZY Nasdaq
- TWIN Nasdaq
- Market Cap
- INZY 188.2M
- TWIN 152.3M
- IPO Year
- INZY 2020
- TWIN N/A
- Fundamental
- Price
- INZY $1.36
- TWIN $11.25
- Analyst Decision
- INZY Strong Buy
- TWIN
- Analyst Count
- INZY 8
- TWIN 0
- Target Price
- INZY $17.75
- TWIN N/A
- AVG Volume (30 Days)
- INZY 1.0M
- TWIN 14.5K
- Earning Date
- INZY 03-11-2025
- TWIN 02-05-2025
- Dividend Yield
- INZY N/A
- TWIN 1.44%
- EPS Growth
- INZY N/A
- TWIN N/A
- EPS
- INZY N/A
- TWIN 0.68
- Revenue
- INZY N/A
- TWIN $304,470,000.00
- Revenue This Year
- INZY N/A
- TWIN N/A
- Revenue Next Year
- INZY N/A
- TWIN N/A
- P/E Ratio
- INZY N/A
- TWIN $16.65
- Revenue Growth
- INZY N/A
- TWIN 6.98
- 52 Week Low
- INZY $1.24
- TWIN $10.22
- 52 Week High
- INZY $7.80
- TWIN $18.00
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- TWIN 46.19
- Support Level
- INZY $1.35
- TWIN $11.17
- Resistance Level
- INZY $1.62
- TWIN $11.66
- Average True Range (ATR)
- INZY 0.13
- TWIN 0.28
- MACD
- INZY 0.04
- TWIN 0.04
- Stochastic Oscillator
- INZY 32.89
- TWIN 48.75
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.